Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116584 · ClinicalTrials.gov registry record · Phase 3
Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients
A Phase 3 study, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT00116584 is a Phase 3 study that has completed, run by University of Louisville. The registered enrollment target is 72 participants.
The verdict
NCT00116584, a Phase 3 study, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether children with moderate to severe bronchiolitis treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven nebulization will have improvements in measurements of airway more rapidly than those treated with conventional air-oxygen driven nebulization.
Interventions
- DRUG heliox
- DRUG oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2004-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116584
The ClinicalTrials.gov registry entry for NCT00116584 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which heliox is the first listed.
NCT00116584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116584 about?
NCT00116584 is a clinical study titled "Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients". The purpose of this study is to assess whether children with moderate to severe bronchiolitis treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven nebulization will have improvements in measurements of airway more rapidly than those treated with conventional air-...
What is the current status of trial NCT00116584?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2004-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00116584?
The interventions under investigation include: heliox (DRUG), oxygen (DRUG).
Who is sponsoring clinical trial NCT00116584?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.